BillionToOne combines 64% Q2 revenue growth, 70.5% gross margins, differentiated molecular diagnostics, and oncology optionality with substantial litigation and valuation-driven downside.
Overview
BillionToOne is a commercial-stage precision diagnostics company founded in 2016 that uses single-molecule next-generation sequencing and QCT technology to quantify cell-free DNA at molecular-level sensitivity. It generates revenue primarily per test from commercial payers, government programs, institutions, and clinical-trial sponsors, with payer agreements covering approximately 300 million U.S. lives. Its flagship prenatal UNITY platform has a differentiated single-maternal-draw approach and captured approximately 15% of the U.S. prenatal market by the end of 2025; oncology products Northstar Select and Northstar Response provide a larger future growth vector. **Q2 2026 revenue increased 64.4% to $109.448 million, gross margin expanded to 70.5%, and GAAP net income reached $8.054 million.** Oncology revenue grew 176% year over year to $13.7 million, while management reiterated 2026 revenue guidance of $450 million to $465 million and positive full-year GAAP operating income. The valuation debate is substantial: failure to raise guidance triggered a sell-off from $105.26 after hours to approximately $91.56, despite constructive analyst targets of $120 to $130. Near-term catalysts include payer-code implementation, sales-force productivity, Epic expansion, Unity Confirm, Northstar Origin, and late-2026 tumor-naive MRD. Principal risks are Illumina patent litigation, regulatory change, reimbursement volatility, and infrastructure commitments.